The History of Peptide Regulation: From the 2023 Ban to the 2026 Reversal

The Three-Year Rollercoaster

Between September 2023 and April 2026, the regulatory status of peptide compounds in the United States changed more dramatically than at any point in their history. Nineteen widely used peptides went from legally compoundable, to banned, to partially restored — with the final chapter still being written as the FDA's advisory committee prepares to meet in July 2026.

This is the full timeline.

Before 2023: The Status Quo

For years, many peptides existed in a relatively stable regulatory environment. Compounds like BPC-157, Thymosin Alpha-1, and various growth hormone secretagogues were available through licensed compounding pharmacies under Section 503A of the Federal Food, Drug, and Cosmetic Act.

The 503A framework allows compounding pharmacies to prepare customized medications based on individual prescriptions, using bulk drug substances that appear on the FDA's approved list. Many peptides were either on this list or existed in a gray area where compounding was tolerated through enforcement discretion.

Simultaneously, a large gray market existed — vendors selling peptides labeled "for research use only" directly to consumers without prescriptions. This market operated largely outside FDA enforcement, though it was technically illegal to sell these products for human use.

September 2023: The Category 2 Hammer

In September 2023, the Biden-era FDA made its most aggressive move against peptide compounding. The agency placed 19 peptides on its Category 2 list — formally titled "Bulk Drug Substances that Raise Significant Safety Risks if They Are Not the Subject of an Approved Application and Not Otherwise Available."

Category 2 designation effectively banned compounding pharmacies from preparing these compounds. The affected peptides included some of the most widely used compounds in regenerative medicine and longevity protocols:

BPC-157
Thymosin Beta-4 (TB-500)
Thymosin Alpha-1
KPV
MOTS-c
Semax
Epitalon
GHK-Cu
Melanotan II
Dihexa
And others

The FDA's rationale centered on safety concerns: insufficient clinical data, potential for misuse, and the lack of FDA-approved versions of these compounds. Critics argued the move was overly broad, that many of these compounds had decades of international clinical use, and that the restriction would drive patients toward unregulated gray-market sources — which is exactly what happened.

2024: The Gray Market Explodes

With legal compounding access cut off, demand didn't decrease — it shifted. Imports of peptide compounds from China roughly doubled year-over-year. Research chemical vendors saw surging sales. Social media became the primary source of dosing information, replacing physician guidance.

The irony was stark: the FDA's safety-motivated restriction made peptide use less safe, not more. Patients who had been using physician-prescribed, pharmacy-compounded peptides were now self-administering products of unknown purity from unregulated sources.

During this period, independent testing revealed that approximately 30% of gray-market peptide products were mislabeled, underdosed, or contaminated. One of the largest vendors, PeptideSciences.com, would later shut down in March 2026 after independent testing revealed purity as low as 75%.

February 27, 2026: The RFK Jr. Announcement

The political landscape shifted dramatically with the change in administration. HHS Secretary Robert F. Kennedy Jr., appearing on The Joe Rogan Experience (Episode #2461), announced that approximately 14 of the 19 Category 2 peptides would be moved back to Category 1 status.

Kennedy characterized the 2023 Category 2 designations as "illegal" and stated that the restrictions had created a dangerous black market. The FDA followed up with formal Category 1 restorations for compounds including:

Thymosin Alpha-1
Sermorelin
Ipamorelin
CJC-1295
AOD-9604

Category 1 status means these compounds can be legally compounded by licensed pharmacies with a physician prescription. It does not mean they are FDA-approved drugs — an important distinction that was widely misreported in the initial media coverage.

April 15, 2026: The Category 2 Removal

The FDA published a formal notice that 12 peptides would be removed from the Category 2 restricted list effective April 22, 2026. The affected compounds included BPC-157, TB-500, Semax, Epitalon, MOTS-c, KPV, Emideltide, GHK-Cu, Melanotan II, Cathelicidin LL-37, Dihexa, and PEG-MGF.

Critically, removal from Category 2 does not automatically authorize compounding. These compounds entered a regulatory gray zone — no longer restricted, but not yet formally evaluated for inclusion on the 503A bulk drug substances list.

To resolve this, the FDA scheduled Pharmacy Compounding Advisory Committee (PCAC) meetings:

July 23-24, 2026: Group 1 — BPC-157, KPV, MOTS-c, TB-500, Emideltide, Epitalon, Semax
By February 2027: Group 2 — GHK-Cu, Melanotan II, Cathelicidin LL-37, Dihexa, PEG-MGF

April 15-22, 2026: Mainstream Media Arrives

The April 15 announcement triggered a wave of mainstream media coverage that brought peptide regulation into the national conversation for the first time:

The Washington Post published "Amid wellness craze, FDA weighs lifting peptide restrictions"
Forbes ran "Wellness Peptides Are Going Mainstream. The Science Hasn't Kept Up"
CNBC reported that Hims & Hers was developing a peptide product line
The National Law Review and FDA Law Blog published detailed legal analyses

The coverage highlighted a tension that defines the current moment: consumer demand is surging, regulatory access is expanding, but the clinical evidence base for many compounds remains limited.

Where We Are Now (April 2026)

The current regulatory landscape has three tiers:

FDA-Approved Peptide Drugs — Semaglutide, tirzepatide, liraglutide, oxytocin, and others. Fully approved through the standard NDA process. Available at retail pharmacies.

Category 1 / Compoundable Peptides — Thymosin Alpha-1, Sermorelin, Ipamorelin, CJC-1295, AOD-9604, and others restored in February 2026. Legally compoundable by licensed pharmacies with a prescription.

Pending PCAC Review — BPC-157, TB-500, KPV, MOTS-c, Semax, Epitalon, Emideltide, and others removed from Category 2 in April 2026. In a regulatory gray zone until PCAC evaluates them in July 2026 and February 2027.

What Happens Next

The PCAC meetings in July 2026 are the next critical milestone. The committee will evaluate each compound and make a recommendation to the FDA on whether it should be included on the 503A bulk drug substances list.

Possible outcomes for each compound:

Favorable recommendation → 503A inclusion: The compound can be legally compounded. This is the best-case scenario for patient access.
Unfavorable recommendation: The FDA may choose not to include the compound, potentially returning it to restricted status.
Deferred for more data: The committee may request additional evidence before making a recommendation, extending the gray zone.

The public comment period for the July meeting closes on July 9, 2026 (docket FDA-2025-N-6895). Oral presentation requests must be submitted by June 30, 2026.

The Bigger Picture

This three-year saga illustrates a fundamental tension in pharmaceutical regulation: the gap between the pace of consumer adoption and the pace of regulatory evaluation.

Peptides became widely used before the regulatory framework caught up. When the FDA tried to restrict access, it didn't reduce use — it made use less safe. The current approach — removing restrictions while scheduling formal evaluation — is an attempt to find a middle ground.

Whether that middle ground holds depends on what the PCAC recommends in July, how the FDA acts on those recommendations, and whether the political winds shift again.

What won't change is the need for clear, independent information about what's legal, what's safe, and how to access peptide therapy through legitimate channels. That's what we're here for.

This article is for educational purposes only and does not constitute medical or legal advice.